THERAPEUTIC INDICATIONS: Treatment of hypercholesterolaemia Adults, adolescents, and children aged 6 years or older with primary hypercholesterolaemia (type lla including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type llb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g., exercise, weight reduction) is inadequate, Adults, adolescents, and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (, LDL apheresis) or if such treatments are not appropriate. Prevention of Cardiovascular Events Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors.

DOSAGE AND METHOD OF ADMINISTRATION: Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines. Rosuvastatin may be given at any time of day, with or without food.